Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Patients With EGFR Activating Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07287904
What this trial is testing

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationAdenocarcinoma Lung+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Testing effectiveness (Phase 2)Ended earlyNCT00988169
What this trial is testing

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 6
Not applicableStudy completedNCT02751879
What this trial is testing

Real World Data on Gi(l)Otrif® Dose Adjustment

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 228
Testing effectiveness (Phase 2)WithdrawnNCT01928160
What this trial is testing

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385483
What this trial is testing

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 19
Not applicableStudy completedNCT03137264
What this trial is testing

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT01217619
What this trial is testing

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Who this might be right for
Non Small Cell Lung Cancer
Baohui Han 25
Testing effectiveness (Phase 2)UnknownNCT03267654
What this trial is testing

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Who this might be right for
Non-small-cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 100
Not applicableUnknownNCT01776684
What this trial is testing

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung Cancer
Samsung Medical Center 200
Large-scale testing (Phase 3)Study completedNCT01667562
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 375
Large-scale testing (Phase 3)Study completedNCT00949650
What this trial is testing

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 345
Post-approval studies (Phase 4)Study completedNCT04511533
What this trial is testing

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Pfizer 101
Testing effectiveness (Phase 2)Study completedNCT04233021
What this trial is testing

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Who this might be right for
Non Small Cell Lung Cancer MetastaticLeptomeningeal MetastasisBrain Metastases+1 more
Intergroupe Francophone de Cancerologie Thoracique 57
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Not applicableUnknownNCT02804217
What this trial is testing

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Who this might be right for
Non-small Cell Lung CancerAquired ResistanceEGFR TKIs
Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)UnknownNCT02930954
What this trial is testing

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Who this might be right for
Non-small-cell Lung Cancer
Caicun Zhou 180
Testing effectiveness (Phase 2)Study completedNCT01469000
What this trial is testing

Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non Small Cell Lung
Eli Lilly and Company 195
Testing effectiveness (Phase 2)Study completedNCT01221077
What this trial is testing

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Who this might be right for
NSCLCNon Small Cell Lung Cancer
Astellas Pharma Inc 88
Testing effectiveness (Phase 2)Ended earlyNCT02949843
What this trial is testing

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Who this might be right for
EGFR Activating MutationRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences 19
Next Page